Compare ACIU & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACIU | LAB |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.6M | 271.0M |
| IPO Year | 2015 | 2008 |
| Metric | ACIU | LAB |
|---|---|---|
| Price | $2.76 | $0.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.57 | N/A |
| AVG Volume (30 Days) | 146.7K | ★ 1.1M |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.54 |
| EPS | N/A | ★ 0.26 |
| Revenue | N/A | ★ $101,937,000.00 |
| Revenue This Year | $422.39 | N/A |
| Revenue Next Year | $377.85 | N/A |
| P/E Ratio | ★ N/A | $2.73 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.10 | $0.63 |
| 52 Week High | $4.00 | $1.72 |
| Indicator | ACIU | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 53.81 |
| Support Level | $2.58 | $0.70 |
| Resistance Level | $2.68 | $0.77 |
| Average True Range (ATR) | 0.14 | 0.03 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 49.81 | 66.97 |
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.